Rheumatology Advance Access published online on June 30, 2009
Rheumatology, doi:10.1093/rheumatology/kep181
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Comment on: Screening for Mycobacterium tuberculosis prior to anti-TNF therapy—an audit of impact of the British Thoracic Society guidelines on rheumatology practice in an area of low Mycobacterium tuberculosis prevalence
1Royal Liverpool University Hospitals, Liverpool, UK
Correspondence to:
Batsi Chikura, Royal Liverpool University Hospitals, Prescot Street, Liverpool L7 8XP, UK. E-mail: docbatsi@aol.com
| The first 10% of the full text of this article appears below. |
SIR, We read the letter by Pradeep et al. [1] with interest. Screening for latent or active tuberculosis (TB) is important prior to initiating TNF-
blockers (anti-TNF-
). In the UK, there is a lack of standard practice in the manner in which
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. D. Pradeep, G. P. R. Clunie, K. Gaffney, N. J. Innes, A. Brooksby, P. Bradley, and A. Gulati Comment on: Screening for Mycobacterium tuberculosis prior to anti-TNF therapy--an audit of impact of the British Thoracic Society guidelines on rheumatology practice in an area of low Mycobacterium tuberculosis prevalence: reply Rheumatology, October 1, 2009; 48(10): 1332 - 1332. [Full Text] [PDF] |
||||
